The primary objectives are to evaluate the safety and efficacy of infusion of the third party fully-characterized clonally derived fetal MSCs (cfMSCs) for the control of severe symptoms associated with acute and chronic immune-related disorders and tissue damage.
Eligibility
Sex
ALL
Min age
1 Year
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria:
1. Informed consent.
2. No available alternative treatment that can reduce the symptoms
3. Patients are required to meet the following inclusion criteria:
* Any patient that has clinically documented abnormal immune or age-related disorders including acute and chronic GVHD. Patients may receive best available treatment for the control of disease symptoms.
* Patients with symptoms associated with genetic defects or infectious diseases are not eligible.
Exclusion Criteria:
1. Inability to give informed consent.
2. Patients with ongoing infection or history of cancer.
3. Patients with poor clinical conditions with the life expectancy of less than 14 days.
4. Pregnancy.
Primary outcome measure(s)
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 — up to one month Safety of cfMSC infusion acute and prolonged
Trial sites (1)
Facility
City
Region
Status
Shenzhen Geno-immune Medical Institute
Shenzhen
Guangdong
More Shenzhen Geno-Immune Medical Institute trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.